Acute Myeloid Leukemia Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Purchase Option

$ 4400
$ 4000
$ 6000

Acute myeloid leukemia is a type of blood cancer,affects white blood cells. It enables progress rapidly, requires immediate treatment. Acute myeloid leukemia symptoms develop over a few weeks and become increasingly more severe. Symptoms may include tiredness, pale skin, breathlessness and unusual & frequent bleeding.

If symptoms are persisted, diagnostic tests may include blood tests, bone marrow test, lumbar puncture and sometimes genomic testing may be suggested. There is no specific cure available for acute myeloid leukemia. But it is treated by the combination of therapies that include chemotherapeutic agents, stem cell transplantation, radiation therapy and targeted therapy.

Key Developments:

  • In October 2017, U.S. Food and Drug Administration granted fast-track designation for development of gilteritinib for adult patients with FLT3 mutation positive relapsed or refractory acute myeloid leukemia.

 

 

 

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases

Location

GEOGRAPHY

PBI Location Map

Acute Myeloid Leukemia Pipeline Drugs Assessment Dynamics

Acute Myeloid Leukemia Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Acute Myeloid Leukemia Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Acute Myeloid Leukemia Pipeline Drugs Assessment Segmentation

By Route of Administration
  • Oral
  • Parenteral
  • Others
By Trial Phase
  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

1. Executive Summary

 2. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Introduction

 2.1. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Taxonomy

2.2. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Definitions

2.2.1. Route of Administration

2.2.2. Trail Phase

3. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis

3.6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Competition Landscape

3.7. Epidemiology

4. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis,2019 - 2023 and Forecast, 2024 - 2030

4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

5. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1. Oral

5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

 5.2. Parenteral

5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Others

5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market, By Trial Phase, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.1. Pre-clinical phase

6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Phase-I

6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Phase II

6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Phase-III

6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

7. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1. North America

7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Europe

7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Asia-Pacific

7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Latin America

7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Middle East and Africa

7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Global Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 2024

8. North America Acute Myeloid Leukemia Pipeline Drugs Assessment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

8.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

8.1.1. Oral

8.1.2. Parenteral

8.1.3. Others

8.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Pre-clinical phase

8.2.2. Phase-I

8.2.3. Phase II

8.2.4. Phase-III

8.3. Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.3.1. U.S.

8.3.2. Canada

8.4. North America Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 2024

8.5. North America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics Trends

9. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

9.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Oral

9.1.2. Parenteral

9.1.3. Others

9.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Pre-clinical phase

9.2.2. Phase-I

9.2.3. Phase II

9.2.4. Phase-III

9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.3.1. Germany

9.3.2. UK

9.3.3. France

9.3.4. Spain

9.3.5. Italy

9.3.6. Russia

9.3.7. Poland

9.3.8. Rest of Europe

9.4. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 2024

9.5. Europe Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics Trends

10. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

10.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Oral

10.1.2. Parenteral

10.1.3. Others

10.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Pre-clinical phase

10.2.2. Phase-I

10.2.3. Phase II

10.2.4. Phase-III

10.3. Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

10.3.1. Japan

10.3.2. China

10.3.3. India

10.3.4. ASEAN

10.3.5. Australia & New Zealand

10.3.6. Rest of Asia-Pacific

10.4. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 2024

10.5. Asia-Pacific Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics Trends

11. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

11.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Oral

11.1.2. Parenteral

11.1.3. Others

11.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Pre-clinical phase

11.2.2. Phase-I

11.2.3. Phase II

11.2.4. Phase-III

11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.3.1. Brazil

11.3.2. Mexico

11.3.3. Argentina

11.3.4. Venezuela

11.3.5. Rest of Latin America

11.4. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 2024

11.5. Latin America Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics Trends

12. Middle East and Africa Acute Myeloid Leukemia Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)

12.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Oral

12.1.2. Parenteral

12.1.3. Others

12.2. Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Pre-clinical phase

12.2.2. Phase-I

12.2.3. Phase II

12.2.4. Phase-III

12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.3.1. Gulf Cooperation Council (GCC) Countries

12.3.2. Israel

12.3.3. South Africa

12.3.4. Rest of MEA

12.4. MEA Acute Myeloid Leukemia Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trial Phase, and Region, 2018 2024

12.5. MEA Acute Myeloid Leukemia Pipeline Drugs Assessment Market Dynamics Trends

13. Competition Landscape

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Drug Class& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Cyclacel Pharmaceuticals Inc. (U.S.)

13.2.2. Johnson & Johnson Services, Inc. (U.S.)

13.2.3. Novartis AG (Switzerland)

13.2.4. H. BoehringerSohn AG &Ko. KG (Germany)

14. Research Methodology

15. Key Assumptions and Acronyms

  • Cyclacel Pharmaceuticals Inc. (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • H. BoehringerSohn AG &Ko. KG (Germany)

Adjacent Markets

Single-cell Technologies Market
Live Cell Imaging Market
Infusion Pumps Market
Enteral Feeding Pumps Market
X-linked Hypophosphatemia (XLH) Market
Tumor-induced Osteomalacia (TIO) Drugs Market